NuVasive, Inc.
NuVasive, Inc. (NUVA) Stock Competitors & Peer Comparison
See (NUVA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUVA | $39.75 | -2.24% | 2.1B | 75.00 | $0.53 | N/A |
| ABT | $131.02 | -0.26% | 228B | 16.44 | $7.97 | +1.78% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $102.64 | -0.10% | 152B | 60.72 | $1.69 | N/A |
| SYK | $376.61 | -0.02% | 144B | 49.87 | $7.55 | +0.88% |
| MDT | $92.08 | -0.71% | 118B | 25.50 | $3.61 | +3.06% |
| EW | $76.93 | -1.57% | 45.2B | 32.18 | $2.39 | N/A |
| DXCM | $80.17 | +2.98% | 31.4B | 56.46 | $1.42 | N/A |
| PHG | $26.99 | +1.16% | 25.7B | 142.03 | $0.19 | +3.29% |
| STE | $243.76 | +0.89% | 24B | 37.33 | $6.53 | +0.94% |
Stock Comparison
NUVA vs ABT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABT has a market cap of 228B. Regarding current trading prices, NUVA is priced at $39.75, while ABT trades at $131.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ABT's P/E ratio is 16.44. In terms of profitability, NUVA's ROE is +0.05%, compared to ABT's ROE of +0.32%. Regarding short-term risk, NUVA is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ABT's competition here
NUVA vs BSX-PA Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NUVA is priced at $39.75, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BSX-PA's competition here
NUVA vs BSX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX has a market cap of 152B. Regarding current trading prices, NUVA is priced at $39.75, while BSX trades at $102.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSX's P/E ratio is 60.72. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BSX's competition here
NUVA vs SYK Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SYK has a market cap of 144B. Regarding current trading prices, NUVA is priced at $39.75, while SYK trades at $376.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SYK's P/E ratio is 49.87. In terms of profitability, NUVA's ROE is +0.05%, compared to SYK's ROE of +0.14%. Regarding short-term risk, NUVA is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SYK's competition here
NUVA vs MDT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MDT has a market cap of 118B. Regarding current trading prices, NUVA is priced at $39.75, while MDT trades at $92.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MDT's P/E ratio is 25.50. In terms of profitability, NUVA's ROE is +0.05%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check MDT's competition here
NUVA vs EW Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, EW has a market cap of 45.2B. Regarding current trading prices, NUVA is priced at $39.75, while EW trades at $76.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas EW's P/E ratio is 32.18. In terms of profitability, NUVA's ROE is +0.05%, compared to EW's ROE of +0.41%. Regarding short-term risk, NUVA is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check EW's competition here
NUVA vs DXCM Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, DXCM has a market cap of 31.4B. Regarding current trading prices, NUVA is priced at $39.75, while DXCM trades at $80.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas DXCM's P/E ratio is 56.46. In terms of profitability, NUVA's ROE is +0.05%, compared to DXCM's ROE of +0.26%. Regarding short-term risk, NUVA is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check DXCM's competition here
NUVA vs PHG Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, NUVA is priced at $39.75, while PHG trades at $26.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PHG's P/E ratio is 142.03. In terms of profitability, NUVA's ROE is +0.05%, compared to PHG's ROE of +0.01%. Regarding short-term risk, NUVA is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check PHG's competition here
NUVA vs STE Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, STE has a market cap of 24B. Regarding current trading prices, NUVA is priced at $39.75, while STE trades at $243.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas STE's P/E ratio is 37.33. In terms of profitability, NUVA's ROE is +0.05%, compared to STE's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check STE's competition here
NUVA vs PODD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PODD has a market cap of 21.8B. Regarding current trading prices, NUVA is priced at $39.75, while PODD trades at $309.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PODD's P/E ratio is 94.11. In terms of profitability, NUVA's ROE is +0.05%, compared to PODD's ROE of +0.21%. Regarding short-term risk, NUVA is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check PODD's competition here
NUVA vs ZBH Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZBH has a market cap of 20.2B. Regarding current trading prices, NUVA is priced at $39.75, while ZBH trades at $101.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ZBH's P/E ratio is 24.83. In terms of profitability, NUVA's ROE is +0.05%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NUVA is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ZBH's competition here
NUVA vs ABMD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NUVA is priced at $39.75, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NUVA's ROE is +0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ABMD's competition here
NUVA vs SNN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SNN has a market cap of 15.8B. Regarding current trading prices, NUVA is priced at $39.75, while SNN trades at $36.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SNN's P/E ratio is 32.35. In terms of profitability, NUVA's ROE is +0.05%, compared to SNN's ROE of +0.09%. Regarding short-term risk, NUVA is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SNN's competition here
NUVA vs SWAV Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NUVA is priced at $39.75, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NUVA's ROE is +0.05%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NUVA is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SWAV's competition here
NUVA vs ALGN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ALGN has a market cap of 10.2B. Regarding current trading prices, NUVA is priced at $39.75, while ALGN trades at $140.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ALGN's P/E ratio is 23.73. In terms of profitability, NUVA's ROE is +0.05%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NUVA is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ALGN's competition here
NUVA vs PEN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PEN has a market cap of 9.7B. Regarding current trading prices, NUVA is priced at $39.75, while PEN trades at $248.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PEN's P/E ratio is 65.85. In terms of profitability, NUVA's ROE is +0.05%, compared to PEN's ROE of +0.12%. Regarding short-term risk, NUVA is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PEN's competition here
NUVA vs GMED Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, GMED has a market cap of 8.4B. Regarding current trading prices, NUVA is priced at $39.75, while GMED trades at $61.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas GMED's P/E ratio is 23.98. In terms of profitability, NUVA's ROE is +0.05%, compared to GMED's ROE of +0.09%. Regarding short-term risk, NUVA is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check GMED's competition here
NUVA vs BIO Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO has a market cap of 7.4B. Regarding current trading prices, NUVA is priced at $39.75, while BIO trades at $274.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BIO's P/E ratio is 24.77. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO's ROE of +0.05%. Regarding short-term risk, NUVA is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BIO's competition here
NUVA vs BIO-B Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, NUVA is priced at $39.75, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO-B's ROE of +0.05%. Regarding short-term risk, NUVA is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BIO-B's competition here
NUVA vs IRTC Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRTC has a market cap of 5.2B. Regarding current trading prices, NUVA is priced at $39.75, while IRTC trades at $162.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IRTC's P/E ratio is -55.60. In terms of profitability, NUVA's ROE is +0.05%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, NUVA is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check IRTC's competition here
NUVA vs GKOS Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, GKOS has a market cap of 5.1B. Regarding current trading prices, NUVA is priced at $39.75, while GKOS trades at $89.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas GKOS's P/E ratio is -55.49. In terms of profitability, NUVA's ROE is +0.05%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, NUVA is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check GKOS's competition here
NUVA vs BRKR Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BRKR has a market cap of 4.9B. Regarding current trading prices, NUVA is priced at $39.75, while BRKR trades at $32.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BRKR's P/E ratio is 62.23. In terms of profitability, NUVA's ROE is +0.05%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, NUVA is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BRKR's competition here
NUVA vs NARI Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NUVA is priced at $39.75, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NARI's P/E ratio is -59.24. In terms of profitability, NUVA's ROE is +0.05%, compared to NARI's ROE of -0.17%. Regarding short-term risk, NUVA is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check NARI's competition here
NUVA vs TMDX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMDX has a market cap of 4.5B. Regarding current trading prices, NUVA is priced at $39.75, while TMDX trades at $131.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TMDX's P/E ratio is 65.89. In terms of profitability, NUVA's ROE is +0.05%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, NUVA is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TMDX's competition here
NUVA vs ITGR Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ITGR has a market cap of 3.8B. Regarding current trading prices, NUVA is priced at $39.75, while ITGR trades at $107.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ITGR's P/E ratio is 45.82. In terms of profitability, NUVA's ROE is +0.05%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, NUVA is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ITGR's competition here
NUVA vs AXNX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NUVA is priced at $39.75, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NUVA's ROE is +0.05%, compared to AXNX's ROE of -0.02%. Regarding short-term risk, NUVA is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check AXNX's competition here
NUVA vs LIVN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LIVN has a market cap of 2.8B. Regarding current trading prices, NUVA is priced at $39.75, while LIVN trades at $50.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LIVN's P/E ratio is -13.05. In terms of profitability, NUVA's ROE is +0.05%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, NUVA is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check LIVN's competition here
NUVA vs INSP Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INSP has a market cap of 2.5B. Regarding current trading prices, NUVA is priced at $39.75, while INSP trades at $83.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INSP's P/E ratio is 48.24. In terms of profitability, NUVA's ROE is +0.05%, compared to INSP's ROE of +0.08%. Regarding short-term risk, NUVA is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check INSP's competition here
NUVA vs ATEC Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ATEC has a market cap of 2.3B. Regarding current trading prices, NUVA is priced at $39.75, while ATEC trades at $15.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ATEC's P/E ratio is -13.91. In terms of profitability, NUVA's ROE is +0.05%, compared to ATEC's ROE of -2.52%. Regarding short-term risk, NUVA is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ATEC's competition here
NUVA vs PRCT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PRCT has a market cap of 2.1B. Regarding current trading prices, NUVA is priced at $39.75, while PRCT trades at $38.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PRCT's P/E ratio is -25.06. In terms of profitability, NUVA's ROE is +0.05%, compared to PRCT's ROE of -0.24%. Regarding short-term risk, NUVA is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PRCT's competition here
NUVA vs AORT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AORT has a market cap of 2.1B. Regarding current trading prices, NUVA is priced at $39.75, while AORT trades at $43.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AORT's P/E ratio is -102.02. In terms of profitability, NUVA's ROE is +0.05%, compared to AORT's ROE of -0.06%. Regarding short-term risk, NUVA is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check AORT's competition here
NUVA vs UFPT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, NUVA is priced at $39.75, while UFPT trades at $219.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas UFPT's P/E ratio is 25.53. In terms of profitability, NUVA's ROE is +0.05%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, NUVA is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check UFPT's competition here
NUVA vs CNMD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, NUVA is priced at $39.75, while CNMD trades at $54.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CNMD's P/E ratio is 15.26. In terms of profitability, NUVA's ROE is +0.05%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check CNMD's competition here
NUVA vs HSKA Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NUVA's ROE is +0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NUVA is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check HSKA's competition here
NUVA vs AHCO Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75, while AHCO trades at $9.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AHCO's P/E ratio is 17.67. In terms of profitability, NUVA's ROE is +0.05%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, NUVA is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check AHCO's competition here
NUVA vs SSII Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SSII has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75, while SSII trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SSII's P/E ratio is -109.83. In terms of profitability, NUVA's ROE is +0.05%, compared to SSII's ROE of -1.05%. Regarding short-term risk, NUVA is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SSII's competition here
NUVA vs SILK Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SILK's P/E ratio is -18.96. In terms of profitability, NUVA's ROE is +0.05%, compared to SILK's ROE of -0.20%. Regarding short-term risk, NUVA is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SILK's competition here
NUVA vs FNA Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas FNA's P/E ratio is -19.83. In terms of profitability, NUVA's ROE is +0.05%, compared to FNA's ROE of -0.36%. Regarding short-term risk, NUVA is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check FNA's competition here
NUVA vs IART Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while IART trades at $13.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IART's P/E ratio is -2.11. In terms of profitability, NUVA's ROE is +0.05%, compared to IART's ROE of -0.36%. Regarding short-term risk, NUVA is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check IART's competition here
NUVA vs INMD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INMD has a market cap of 989.1M. Regarding current trading prices, NUVA is priced at $39.75, while INMD trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INMD's P/E ratio is 5.97. In terms of profitability, NUVA's ROE is +0.05%, compared to INMD's ROE of +0.27%. Regarding short-term risk, NUVA is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check INMD's competition here
NUVA vs ESTA Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ESTA has a market cap of 972.2M. Regarding current trading prices, NUVA is priced at $39.75, while ESTA trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ESTA's P/E ratio is -10.92. In terms of profitability, NUVA's ROE is +0.05%, compared to ESTA's ROE of -2.41%. Regarding short-term risk, NUVA is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ESTA's competition here
NUVA vs IRMD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRMD has a market cap of 928.6M. Regarding current trading prices, NUVA is priced at $39.75, while IRMD trades at $73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IRMD's P/E ratio is 45.34. In terms of profitability, NUVA's ROE is +0.05%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NUVA is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check IRMD's competition here
NUVA vs CSII Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NUVA is priced at $39.75, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CSII's P/E ratio is -20.83. In terms of profitability, NUVA's ROE is +0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NUVA is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check CSII's competition here
NUVA vs TNDM Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TNDM has a market cap of 750.4M. Regarding current trading prices, NUVA is priced at $39.75, while TNDM trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TNDM's P/E ratio is -3.61. In terms of profitability, NUVA's ROE is +0.05%, compared to TNDM's ROE of -1.04%. Regarding short-term risk, NUVA is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TNDM's competition here
NUVA vs CRY Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NUVA is priced at $39.75, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CRY's P/E ratio is 425.71. In terms of profitability, NUVA's ROE is +0.05%, compared to CRY's ROE of -0.05%. Regarding short-term risk, NUVA is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CRY's competition here
NUVA vs SIBN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SIBN has a market cap of 655.7M. Regarding current trading prices, NUVA is priced at $39.75, while SIBN trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SIBN's P/E ratio is -26.67. In terms of profitability, NUVA's ROE is +0.05%, compared to SIBN's ROE of -0.14%. Regarding short-term risk, NUVA is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SIBN's competition here
NUVA vs AXGN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXGN has a market cap of 651.5M. Regarding current trading prices, NUVA is priced at $39.75, while AXGN trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AXGN's P/E ratio is -141.60. In terms of profitability, NUVA's ROE is +0.05%, compared to AXGN's ROE of -0.04%. Regarding short-term risk, NUVA is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check AXGN's competition here
NUVA vs APEN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NUVA is priced at $39.75, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas APEN's P/E ratio is -9.43. In terms of profitability, NUVA's ROE is +0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NUVA is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check APEN's competition here
NUVA vs OFIX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OFIX has a market cap of 545M. Regarding current trading prices, NUVA is priced at $39.75, while OFIX trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OFIX's P/E ratio is -4.35. In terms of profitability, NUVA's ROE is +0.05%, compared to OFIX's ROE of -0.25%. Regarding short-term risk, NUVA is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check OFIX's competition here
NUVA vs SRDX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SRDX has a market cap of 542.2M. Regarding current trading prices, NUVA is priced at $39.75, while SRDX trades at $37.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SRDX's P/E ratio is -30.58. In terms of profitability, NUVA's ROE is +0.05%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, NUVA is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SRDX's competition here
NUVA vs ZIMV Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZIMV has a market cap of 531.6M. Regarding current trading prices, NUVA is priced at $39.75, while ZIMV trades at $18.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ZIMV's P/E ratio is -27.32. In terms of profitability, NUVA's ROE is +0.05%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, NUVA is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ZIMV's competition here
NUVA vs CTKB Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CTKB has a market cap of 512.7M. Regarding current trading prices, NUVA is priced at $39.75, while CTKB trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CTKB's P/E ratio is -80.60. In terms of profitability, NUVA's ROE is +0.05%, compared to CTKB's ROE of -0.02%. Regarding short-term risk, NUVA is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CTKB's competition here
NUVA vs SMLR Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SMLR has a market cap of 511.4M. Regarding current trading prices, NUVA is priced at $39.75, while SMLR trades at $34.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SMLR's P/E ratio is 7.57. In terms of profitability, NUVA's ROE is +0.05%, compared to SMLR's ROE of +0.17%. Regarding short-term risk, NUVA is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SMLR's competition here
NUVA vs AVNS Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVNS has a market cap of 501.4M. Regarding current trading prices, NUVA is priced at $39.75, while AVNS trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AVNS's P/E ratio is -1.08. In terms of profitability, NUVA's ROE is +0.05%, compared to AVNS's ROE of -0.50%. Regarding short-term risk, NUVA is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check AVNS's competition here
NUVA vs KIDS Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, KIDS has a market cap of 491.7M. Regarding current trading prices, NUVA is priced at $39.75, while KIDS trades at $19.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas KIDS's P/E ratio is -10.89. In terms of profitability, NUVA's ROE is +0.05%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, NUVA is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check KIDS's competition here
NUVA vs BVS Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BVS has a market cap of 489M. Regarding current trading prices, NUVA is priced at $39.75, while BVS trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BVS's P/E ratio is 243.67. In terms of profitability, NUVA's ROE is +0.05%, compared to BVS's ROE of -0.00%. Regarding short-term risk, NUVA is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BVS's competition here
NUVA vs VREX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, VREX has a market cap of 438.7M. Regarding current trading prices, NUVA is priced at $39.75, while VREX trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas VREX's P/E ratio is -3.27. In terms of profitability, NUVA's ROE is +0.05%, compared to VREX's ROE of -0.25%. Regarding short-term risk, NUVA is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check VREX's competition here
NUVA vs CBLL Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CBLL has a market cap of 429M. Regarding current trading prices, NUVA is priced at $39.75, while CBLL trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CBLL's P/E ratio is -3.24. In terms of profitability, NUVA's ROE is +0.05%, compared to CBLL's ROE of -0.48%. Regarding short-term risk, NUVA is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CBLL's competition here
NUVA vs TMCI Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMCI has a market cap of 412.5M. Regarding current trading prices, NUVA is priced at $39.75, while TMCI trades at $6.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TMCI's P/E ratio is -8.27. In terms of profitability, NUVA's ROE is +0.05%, compared to TMCI's ROE of -0.47%. Regarding short-term risk, NUVA is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TMCI's competition here
NUVA vs SENS Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SENS has a market cap of 385.7M. Regarding current trading prices, NUVA is priced at $39.75, while SENS trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SENS's P/E ratio is -4.73. In terms of profitability, NUVA's ROE is +0.05%, compared to SENS's ROE of -12.27%. Regarding short-term risk, NUVA is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SENS's competition here
NUVA vs PACB Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PACB has a market cap of 363.4M. Regarding current trading prices, NUVA is priced at $39.75, while PACB trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PACB's P/E ratio is -0.54. In terms of profitability, NUVA's ROE is +0.05%, compared to PACB's ROE of -1.89%. Regarding short-term risk, NUVA is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PACB's competition here
NUVA vs SNWV Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SNWV has a market cap of 357.3M. Regarding current trading prices, NUVA is priced at $39.75, while SNWV trades at $41.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SNWV's P/E ratio is -5.07. In terms of profitability, NUVA's ROE is +0.05%, compared to SNWV's ROE of +1.45%. Regarding short-term risk, NUVA is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SNWV's competition here
NUVA vs BFLY Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BFLY has a market cap of 349.9M. Regarding current trading prices, NUVA is priced at $39.75, while BFLY trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BFLY's P/E ratio is -4.96. In terms of profitability, NUVA's ROE is +0.05%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, NUVA is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BFLY's competition here
NUVA vs BFLY-WT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BFLY-WT has a market cap of 329.7M. Regarding current trading prices, NUVA is priced at $39.75, while BFLY-WT trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, NUVA is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BFLY-WT's competition here
NUVA vs RXST Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RXST has a market cap of 300.7M. Regarding current trading prices, NUVA is priced at $39.75, while RXST trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RXST's P/E ratio is -9.19. In terms of profitability, NUVA's ROE is +0.05%, compared to RXST's ROE of -0.12%. Regarding short-term risk, NUVA is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check RXST's competition here
NUVA vs NPCE Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NPCE has a market cap of 299.5M. Regarding current trading prices, NUVA is priced at $39.75, while NPCE trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NPCE's P/E ratio is -11.13. In terms of profitability, NUVA's ROE is +0.05%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, NUVA is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check NPCE's competition here
NUVA vs CLPT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CLPT has a market cap of 297.9M. Regarding current trading prices, NUVA is priced at $39.75, while CLPT trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CLPT's P/E ratio is -13.87. In terms of profitability, NUVA's ROE is +0.05%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, NUVA is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CLPT's competition here
NUVA vs CATX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CATX has a market cap of 294.7M. Regarding current trading prices, NUVA is priced at $39.75, while CATX trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CATX's P/E ratio is -3.23. In terms of profitability, NUVA's ROE is +0.05%, compared to CATX's ROE of -0.27%. Regarding short-term risk, NUVA is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CATX's competition here
NUVA vs VMD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, VMD has a market cap of 288.6M. Regarding current trading prices, NUVA is priced at $39.75, while VMD trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas VMD's P/E ratio is 21.88. In terms of profitability, NUVA's ROE is +0.05%, compared to VMD's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check VMD's competition here
NUVA vs NNOX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NNOX has a market cap of 284.1M. Regarding current trading prices, NUVA is priced at $39.75, while NNOX trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NNOX's P/E ratio is -4.90. In terms of profitability, NUVA's ROE is +0.05%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, NUVA is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check NNOX's competition here
NUVA vs TCMD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TCMD has a market cap of 280.2M. Regarding current trading prices, NUVA is priced at $39.75, while TCMD trades at $12.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TCMD's P/E ratio is 20.27. In terms of profitability, NUVA's ROE is +0.05%, compared to TCMD's ROE of +0.07%. Regarding short-term risk, NUVA is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TCMD's competition here
NUVA vs CERS Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CERS has a market cap of 247.3M. Regarding current trading prices, NUVA is priced at $39.75, while CERS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CERS's P/E ratio is -12.90. In terms of profitability, NUVA's ROE is +0.05%, compared to CERS's ROE of -0.34%. Regarding short-term risk, NUVA is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CERS's competition here
NUVA vs MASS Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MASS has a market cap of 233.5M. Regarding current trading prices, NUVA is priced at $39.75, while MASS trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MASS's P/E ratio is -2.74. In terms of profitability, NUVA's ROE is +0.05%, compared to MASS's ROE of -0.13%. Regarding short-term risk, NUVA is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check MASS's competition here
NUVA vs BWAY Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BWAY has a market cap of 230.4M. Regarding current trading prices, NUVA is priced at $39.75, while BWAY trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BWAY's P/E ratio is 55.41. In terms of profitability, NUVA's ROE is +0.05%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, NUVA is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BWAY's competition here
NUVA vs OM Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OM has a market cap of 225.1M. Regarding current trading prices, NUVA is priced at $39.75, while OM trades at $12.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OM's P/E ratio is -0.68. In terms of profitability, NUVA's ROE is +0.05%, compared to OM's ROE of -0.98%. Regarding short-term risk, NUVA is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check OM's competition here
NUVA vs NVRO Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NUVA is priced at $39.75, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NUVA's ROE is +0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NUVA is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check NVRO's competition here
NUVA vs SGHT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SGHT has a market cap of 222.6M. Regarding current trading prices, NUVA is priced at $39.75, while SGHT trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SGHT's P/E ratio is -4.34. In terms of profitability, NUVA's ROE is +0.05%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, NUVA is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SGHT's competition here
NUVA vs QTRX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, QTRX has a market cap of 221.2M. Regarding current trading prices, NUVA is priced at $39.75, while QTRX trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas QTRX's P/E ratio is -2.63. In terms of profitability, NUVA's ROE is +0.05%, compared to QTRX's ROE of -0.22%. Regarding short-term risk, NUVA is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check QTRX's competition here
NUVA vs EYES Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NUVA is priced at $39.75, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas EYES's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to EYES's ROE of -0.26%. Regarding short-term risk, NUVA is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check EYES's competition here
NUVA vs INGN Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INGN has a market cap of 205M. Regarding current trading prices, NUVA is priced at $39.75, while INGN trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INGN's P/E ratio is -7.15. In terms of profitability, NUVA's ROE is +0.05%, compared to INGN's ROE of -0.14%. Regarding short-term risk, NUVA is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check INGN's competition here
NUVA vs CVRX Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CVRX has a market cap of 196.4M. Regarding current trading prices, NUVA is priced at $39.75, while CVRX trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CVRX's P/E ratio is -3.65. In terms of profitability, NUVA's ROE is +0.05%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, NUVA is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CVRX's competition here
NUVA vs MGRM Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MGRM has a market cap of 194.2M. Regarding current trading prices, NUVA is priced at $39.75, while MGRM trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MGRM's P/E ratio is -10.74. In terms of profitability, NUVA's ROE is +0.05%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, NUVA is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check MGRM's competition here
NUVA vs PROF Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PROF has a market cap of 167.4M. Regarding current trading prices, NUVA is priced at $39.75, while PROF trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PROF's P/E ratio is -4.60. In terms of profitability, NUVA's ROE is +0.05%, compared to PROF's ROE of -0.70%. Regarding short-term risk, NUVA is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PROF's competition here
NUVA vs ELMD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ELMD has a market cap of 162.4M. Regarding current trading prices, NUVA is priced at $39.75, while ELMD trades at $19.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ELMD's P/E ratio is 24.51. In terms of profitability, NUVA's ROE is +0.05%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, NUVA is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ELMD's competition here
NUVA vs LNSR Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LNSR has a market cap of 154.2M. Regarding current trading prices, NUVA is priced at $39.75, while LNSR trades at $12.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LNSR's P/E ratio is -3.07. In terms of profitability, NUVA's ROE is +0.05%, compared to LNSR's ROE of +51.79%. Regarding short-term risk, NUVA is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check LNSR's competition here
NUVA vs RCEL Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RCEL has a market cap of 146.9M. Regarding current trading prices, NUVA is priced at $39.75, while RCEL trades at $5.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RCEL's P/E ratio is -2.80. In terms of profitability, NUVA's ROE is +0.05%, compared to RCEL's ROE of +279.91%. Regarding short-term risk, NUVA is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check RCEL's competition here
NUVA vs BSGM Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSGM has a market cap of 146.3M. Regarding current trading prices, NUVA is priced at $39.75, while BSGM trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSGM's P/E ratio is -8.81. In terms of profitability, NUVA's ROE is +0.05%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, NUVA is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BSGM's competition here
NUVA vs TLSI Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TLSI has a market cap of 138.6M. Regarding current trading prices, NUVA is priced at $39.75, while TLSI trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TLSI's P/E ratio is -3.32. In terms of profitability, NUVA's ROE is +0.05%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, NUVA is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TLSI's competition here
NUVA vs AVR Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVR has a market cap of 138.4M. Regarding current trading prices, NUVA is priced at $39.75, while AVR trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AVR's P/E ratio is -1.07. In terms of profitability, NUVA's ROE is +0.05%, compared to AVR's ROE of -2.92%. Regarding short-term risk, NUVA is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check AVR's competition here
NUVA vs OWLT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OWLT has a market cap of 137.7M. Regarding current trading prices, NUVA is priced at $39.75, while OWLT trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OWLT's P/E ratio is -2.15. In terms of profitability, NUVA's ROE is +0.05%, compared to OWLT's ROE of +2.12%. Regarding short-term risk, NUVA is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check OWLT's competition here
NUVA vs MXCT Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MXCT has a market cap of 135.4M. Regarding current trading prices, NUVA is priced at $39.75, while MXCT trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MXCT's P/E ratio is -3.02. In terms of profitability, NUVA's ROE is +0.05%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, NUVA is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check MXCT's competition here
NUVA vs ANIK Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ANIK has a market cap of 125.7M. Regarding current trading prices, NUVA is priced at $39.75, while ANIK trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ANIK's P/E ratio is -9.69. In terms of profitability, NUVA's ROE is +0.05%, compared to ANIK's ROE of -0.35%. Regarding short-term risk, NUVA is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ANIK's competition here
NUVA vs RPID Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RPID has a market cap of 117.5M. Regarding current trading prices, NUVA is priced at $39.75, while RPID trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RPID's P/E ratio is -2.60. In terms of profitability, NUVA's ROE is +0.05%, compared to RPID's ROE of -0.56%. Regarding short-term risk, NUVA is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check RPID's competition here
NUVA vs LUCD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LUCD has a market cap of 107.9M. Regarding current trading prices, NUVA is priced at $39.75, while LUCD trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LUCD's P/E ratio is -0.85. In terms of profitability, NUVA's ROE is +0.05%, compared to LUCD's ROE of -11.07%. Regarding short-term risk, NUVA is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check LUCD's competition here
NUVA vs ICAD Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NUVA is priced at $39.75, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NUVA's ROE is +0.05%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, NUVA is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ICAD's competition here
NUVA vs NSPR Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NSPR has a market cap of 105.1M. Regarding current trading prices, NUVA is priced at $39.75, while NSPR trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NSPR's P/E ratio is -3.11. In terms of profitability, NUVA's ROE is +0.05%, compared to NSPR's ROE of -1.31%. Regarding short-term risk, NUVA is less volatile compared to NSPR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check NSPR's competition here
NUVA vs HJLI Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NUVA is priced at $39.75, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HJLI's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to HJLI's ROE of -0.00%. Regarding short-term risk, NUVA is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check HJLI's competition here
NUVA vs ASXC Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NUVA is priced at $39.75, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NUVA's ROE is +0.05%, compared to ASXC's ROE of -56.86%. Regarding short-term risk, NUVA is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ASXC's competition here
NUVA vs FONR Comparison August 2025
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, FONR has a market cap of 93.7M. Regarding current trading prices, NUVA is priced at $39.75, while FONR trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas FONR's P/E ratio is 12.09. In terms of profitability, NUVA's ROE is +0.05%, compared to FONR's ROE of +0.07%. Regarding short-term risk, NUVA is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check FONR's competition here